Tyra Biosciences, Inc.
TYRA$1.77B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCARLSBAD60 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 13, 2026
7wMarket Overview
Stock performance and key metrics
TYRA News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
TYRA-300 60mg
Low-grade NMIBC
TYRA-300
Locally Advanced Urothelial Carcinoma
TYRA-300 0.125 mg/kg
Achondroplasia
Dabogratinib (TYRA-300) 60mg
Low Grade Upper Tract Urothelial Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TYRA-300 60mg | Phase 2 | Low-grade NMIBC | - | - |
TYRA-300 | Phase 2 | Locally Advanced Urothelial Carcinoma | - | - |
TYRA-300 0.125 mg/kg | Phase 2 | Achondroplasia | - | - |
Dabogratinib (TYRA-300) 60mg | Phase 2 | Low Grade Upper Tract Urothelial Carcinoma | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply